| Name | Seganserin |
| Description | Seganserin, a non-selective 5-hydroxytryptamine 2-HT receptor antagonist, reversed the inhibitory effects of fluoxetine and quipazine on luteinizing hormone-induced hyperphagia, depression and nociception, and reversed the antidepressant and analgesic effects induced by fluoxetine and quipazine. |
| In vivo | Seganserin (2 mg/kg, i.p.; mice), a 5-HT(2) receptor antagonist pretreatment significantly reversed fluoxetine and quipazine-induced antidepressant and analgesic effects.[2]
Seganserin (2 mg/kg, i.p.; mice), significantly reversed the suppressive effect of fluoxetine and quipazine on progesterone-induced hyperphagia, depression, and algesia in the hot-plate test.[2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 62.5 mg/mL (132.54 mM), Sonication is recommended.
|
| Keywords | 5HTReceptor | 5HT Receptor | 5-HT |
| Inhibitors Related | Alverine citrate | Sevoflurane | Dapoxetine hydrochloride | Cefaclor monohydrate | Clozapine N-Oxide | 1,8-Cineole | Dopamine hydrochloride | Cloperastine hydrochloride | Mianserin hydrochloride | Trazodone hydrochloride | Cinchonidine | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library | GPCR Compound Library | Anti-Cancer Compound Library |
United States
